# Fu-zheng-qu-zhuo Oral Liquid Improves Renal Function in Patients of CKD Stage 3 and 4

Study · id `cardio:ct-nct02275468` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02275468](<https://clinicaltrials.gov/study/NCT02275468>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02275468

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 124 participants.

## Technical summary

Registry record NCT02275468. Randomized; double masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2013-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 124 participants (enrolled count; ClinicalTrials.gov record NCT02275468, source copy `cardio:ctgov-nct02275468-2014-10-27`, retrieved 2026-10-26)
- Start date: 2010-06 (registry gives no type) (ClinicalTrials.gov record NCT02275468, source copy `cardio:ctgov-nct02275468-2014-10-27`, retrieved 2026-10-26)
- Primary completion: 2013-05 (actual) (ClinicalTrials.gov record NCT02275468, source copy `cardio:ctgov-nct02275468-2014-10-27`, retrieved 2026-10-26)
- Completion: 2014-10 (actual) (ClinicalTrials.gov record NCT02275468, source copy `cardio:ctgov-nct02275468-2014-10-27`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02275468, source copy `cardio:ctgov-nct02275468-2014-10-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02275468-2014-10-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Fu-zheng-qu-zhuo Oral Liquid Improves Renal Function in Patients of CKD Stage 3 and 4
- Condition: Stage 3 Chronic Kidney Disease
- Condition: Stage 4 Chronic Kidney Disease
- Intervention (Drug): Fu-zheng-qu-zhuo (FZQZ) oral liquid
- Lead sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Lead sponsor class: OTHER
- Collaborator: Fangshan Hospital of Traditional Chinese Medicine,
- Collaborator class: OTHER
- Collaborator: Peking University First Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences (`cardio:org-guang-anmen-hospital-of-china-academy-of-chinese-medical-0e53a2`)
- Registry lists this organization as a collaborator: Peking University First Hospital (`cardio:org-peking-university-first-hospital`)

## Provenance

Content hash: b20158b5603bb1ed1b0341d524d02afd82991827759673df6de75f6d1893803a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
